Țară: Canada
Limbă: engleză
Sursă: Health Canada
TRANEXAMIC ACID
GENMED A DIVISION OF PFIZER CANADA ULC
B02AA02
TRANEXAMIC ACID
500MG
TABLET
TRANEXAMIC ACID 500MG
ORAL
100
Prescription
HEMOSTATICS
Active ingredient group (AIG) number: 0114760001; AHFS:
APPROVED
2013-07-26
_GD-TRANEXAMIC ACID (tranexamic acid)_ _ _ _Page 1 of 21_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR GD * -TRANEXAMIC ACID Tranexamic acid tablets Tablet, 500 mg, Oral House Standard Antifibrinolytic agent GenMed, a division of Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec, H9J 2M5 Date of Initial Authorization: JUL 26, 2013 Date of Revision: November 23, 2022 Submission Control Number: 265002 * GD is a trademark of Pfizer Canada ULC GenMed, a division of Pfizer Canada ULC., Licensee Pfizer Canada Inc. 2022 _GD-TRANEXAMIC ACID (tranexamic acid)_ _ _ _Page 2 of 21_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 11/2022 7 WARNINGS AND PRECAUTIONS 11/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics.............................................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations .........................................................................................5 4.2 Recommended Dose and Dosage Adjustment.......................................................5 4.5 Missed Dose .......................... Citiți documentul complet